Literature DB >> 1355673

2-Chlorodeoxyadenosine in the treatment of multiple myeloma.

M A Dimopoulos, H M Kantarjian, E H Estey, R Alexanian.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355673

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

Authors:  Marta Chesi; Geoffrey M Matthews; Victoria M Garbitt; Stephen E Palmer; Jake Shortt; Marcus Lefebure; A Keith Stewart; Ricky W Johnstone; P Leif Bergsagel
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

2.  The effects of forodesine in murine and human multiple myeloma cells.

Authors:  Liesbeth Bieghs; Jo Caers; Elke De Bruyne; Els Van Valckenborgh; Fiona Higginbotham; Karin Vanderkerken; Eline Menu
Journal:  Adv Hematol       Date:  2010-10-19

Review 3.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 4.  Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.

Authors:  H J Guchelaar; D J Richel; M R Schaafsma
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

5.  Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.

Authors:  Bo Cai; Shuiliang Wang; Jingcao Huang; Choon-Kee Lee; Chunji Gao; Bolin Liu
Journal:  Am J Transl Res       Date:  2013-01-21       Impact factor: 4.060

6.  Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.

Authors:  Jian Ma; Shuiliang Wang; Ming Zhao; Xin-Sheng Deng; Choon-Kee Lee; Xiao-Dan Yu; Bolin Liu
Journal:  BMC Cancer       Date:  2011-06-16       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.